MTOR and early-onset autosomal dominant Alzheimer disease: The applicability of chronic mTOR attenuation in aging-associated diseases such as cerebrovascular dysfunction and cognitive decline has also been addressed, and significant benefits were shown in experimental animal models of cerebrovascular and neuronal dysfunction, thus suggesting that mTOR inhibitors such as rapamycin may decrease the risk of developing age-associated neurological disorders including vascular dementia and Alzheimer’s disease [110].